Stemline Therapeutics Inc (NASDAQ:STML) – Equities research analysts at Wedbush issued their FY2022 EPS estimates for shares of Stemline Therapeutics in a note issued to investors on Monday. Wedbush analyst D. Nierengarten forecasts that the biopharmaceutical company will earn $2.29 per share for the year.
Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.26). Stemline Therapeutics had a negative return on equity of 94.70% and a negative net margin of 4,689.63%.
A number of other analysts also recently issued reports on the company. BidaskClub downgraded Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a research note on Monday. ValuEngine downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. Finally, Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 15th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $31.33.
Shares of STML stock traded up $0.10 on Wednesday, hitting $13.85. The company’s stock had a trading volume of 360,654 shares, compared to its average volume of 340,275. Stemline Therapeutics has a twelve month low of $7.30 and a twelve month high of $18.75. The firm has a market cap of $425.96, a P/E ratio of -4.68 and a beta of -0.07.
In related news, CEO Ivan Bergstein sold 3,820 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $15.80, for a total transaction of $60,356.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Kenneth Hoberman sold 14,040 shares of the firm’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $13.93, for a total value of $195,577.20. The disclosure for this sale can be found here. Insiders sold a total of 156,418 shares of company stock valued at $2,628,131 over the last ninety days. Corporate insiders own 15.70% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Northern Trust Corp grew its position in Stemline Therapeutics by 18.0% in the 2nd quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock valued at $2,529,000 after acquiring an additional 41,898 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Stemline Therapeutics by 74.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 120,477 shares of the biopharmaceutical company’s stock valued at $1,108,000 after buying an additional 51,578 shares during the period. Lyon Street Capital LLC boosted its stake in shares of Stemline Therapeutics by 331.1% in the 3rd quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after buying an additional 415,867 shares during the period. Virtus Fund Advisers LLC purchased a new position in shares of Stemline Therapeutics in the 4th quarter valued at about $374,000. Finally, Cowen Inc. purchased a new position in shares of Stemline Therapeutics in the 3rd quarter valued at about $420,000. 52.00% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/03/21/stemline-therapeutics-inc-expected-to-post-fy2022-earnings-of-2-29-per-share-stml.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.